Literature DB >> 25920768

Myofiber damage precedes macrophage infiltration after in vivo injury in dysferlin-deficient A/J mouse skeletal muscle.

Joseph A Roche1, Mohan E Tulapurkar2, Amber L Mueller3, Nico van Rooijen4, Jeffrey D Hasday2, Richard M Lovering5, Robert J Bloch3.   

Abstract

Mutations in the dysferlin gene (DYSF) lead to human muscular dystrophies known as dysferlinopathies. The dysferlin-deficient A/J mouse develops a mild myopathy after 6 months of age, and when younger models the subclinical phase of the human disease. We subjected the tibialis anterior muscle of 3- to 4-month-old A/J mice to in vivo large-strain injury (LSI) from lengthening contractions and studied the progression of torque loss, myofiber damage, and inflammation afterward. We report that myofiber damage in A/J mice occurs before inflammatory cell infiltration. Peak edema and inflammation, monitored by magnetic resonance imaging and by immunofluorescence labeling of neutrophils and macrophages, respectively, develop 24 to 72 hours after LSI, well after the appearance of damaged myofibers. Cytokine profiles 72 hours after injury are consistent with extensive macrophage infiltration. Dysferlin-sufficient A/WySnJ mice show much less myofiber damage and inflammation and lesser cytokine levels after LSI than do A/J mice. Partial suppression of macrophage infiltration by systemic administration of clodronate-incorporated liposomes fails to suppress LSI-induced damage or to accelerate torque recovery in A/J mice. The findings from our studies suggest that, although macrophage infiltration is prominent in dysferlin-deficient A/J muscle after LSI, it is the consequence and not the cause of progressive myofiber damage.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25920768      PMCID: PMC4450316          DOI: 10.1016/j.ajpath.2015.02.020

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  38 in total

1.  Physiological and histological changes in skeletal muscle following in vivo gene transfer by electroporation.

Authors:  Joseph A Roche; Diana L Ford-Speelman; Lisa W Ru; Allison L Densmore; Renuka Roche; Patrick W Reed; Robert J Bloch
Journal:  Am J Physiol Cell Physiol       Date:  2011-08-10       Impact factor: 4.249

2.  An in vivo rodent model of contraction-induced injury and non-invasive monitoring of recovery.

Authors:  Richard M Lovering; Joseph A Roche; Mariah H Goodall; Brett B Clark; Alan McMillan
Journal:  J Vis Exp       Date:  2011-05-11       Impact factor: 1.355

3.  Changes in muscle T2 and tissue damage after downhill running in mdx mice.

Authors:  Sunita Mathur; Ravneet S Vohra; Sean A Germain; Sean Forbes; Nathan D Bryant; Krista Vandenborne; Glenn A Walter
Journal:  Muscle Nerve       Date:  2011-04-12       Impact factor: 3.217

4.  Unmasking potential intracellular roles for dysferlin through improved immunolabeling methods.

Authors:  Joseph A Roche; Lisa W Ru; Andrea M O'Neill; Wendy G Resneck; Richard M Lovering; Robert J Bloch
Journal:  J Histochem Cytochem       Date:  2011-11       Impact factor: 2.479

5.  Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer.

Authors:  William Lostal; Marc Bartoli; Nathalie Bourg; Carinne Roudaut; Azeddine Bentaïb; Katsuya Miyake; Nicolas Guerchet; Françoise Fougerousse; Paul McNeil; Isabelle Richard
Journal:  Hum Mol Genet       Date:  2010-02-13       Impact factor: 6.150

6.  Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice.

Authors:  Renzhi Han; Ellie M Frett; Jennifer R Levy; Erik P Rader; John D Lueck; Dimple Bansal; Steven A Moore; Rainer Ng; Daniel Beltrán-Valero de Bernabé; John A Faulkner; Kevin P Campbell
Journal:  J Clin Invest       Date:  2010-11-08       Impact factor: 14.808

7.  Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping.

Authors:  Nicolas Wein; Aurélie Avril; Marc Bartoli; Cyriaque Beley; Soraya Chaouch; Pascal Laforêt; Anthony Behin; Gillian Butler-Browne; Vincent Mouly; Martin Krahn; Luis Garcia; Nicolas Lévy
Journal:  Hum Mutat       Date:  2010-02       Impact factor: 4.878

8.  Extensive mononuclear infiltration and myogenesis characterize recovery of dysferlin-null skeletal muscle from contraction-induced injuries.

Authors:  Joseph A Roche; Richard M Lovering; Renuka Roche; Lisa W Ru; Patrick W Reed; Robert J Bloch
Journal:  Am J Physiol Cell Physiol       Date:  2009-11-18       Impact factor: 4.249

Review 9.  Dysferlinopathies.

Authors:  J Andoni Urtizberea; Guillaume Bassez; France Leturcq; Karine Nguyen; Martin Krahn; Nicolas Levy
Journal:  Neurol India       Date:  2008 Jul-Sep       Impact factor: 2.117

10.  Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism.

Authors:  G Cenacchi; M Fanin; L B De Giorgi; C Angelini
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

View more
  16 in total

Review 1.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

2.  Effect of Ibuprofen on Skeletal Muscle of Dysferlin-Null Mice.

Authors:  Alyssa F Collier; Jessica Gumerson; Kimmo Lehtimäki; Jukka Puoliväli; Jace W Jones; Maureen A Kane; Sankeerth Manne; Andrea O'Neill; Hillarie P Windish; Toni Ahtoniemi; Bradley A Williams; Douglas E Albrecht; Robert J Bloch
Journal:  J Pharmacol Exp Ther       Date:  2017-12-28       Impact factor: 4.030

3.  Myeloid Cell Responses to Contraction-induced Injury Differ in Muscles of Young and Old Mice.

Authors:  Darcée D Sloboda; Lemuel A Brown; Susan V Brooks
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-11-10       Impact factor: 6.053

Review 4.  Engineered skeletal muscles for disease modeling and drug discovery.

Authors:  Jason Wang; Alastair Khodabukus; Lingjun Rao; Keith Vandusen; Nadia Abutaleb; Nenad Bursac
Journal:  Biomaterials       Date:  2019-08-08       Impact factor: 12.479

5.  Cardiac troponin T and autoimmunity in skeletal muscle aging.

Authors:  Tan Zhang; Xin Feng; Juan Dong; Zherong Xu; Bo Feng; Karen M Haas; Peggy M Cawthon; Kristen M Beavers; Barbara Nicklas; Stephen Kritchevsky
Journal:  Geroscience       Date:  2022-01-15       Impact factor: 7.581

6.  Coupling of excitation to Ca2+ release is modulated by dysferlin.

Authors:  Valeriy Lukyanenko; Joaquin M Muriel; Robert J Bloch
Journal:  J Physiol       Date:  2017-06-26       Impact factor: 5.182

7.  Enhanced Muscular Dystrophy from Loss of Dysferlin Is Accompanied by Impaired Annexin A6 Translocation after Sarcolemmal Disruption.

Authors:  Alexis R Demonbreun; Madison V Allen; James L Warner; David Y Barefield; Swathi Krishnan; Kaitlin E Swanson; Judy U Earley; Elizabeth M McNally
Journal:  Am J Pathol       Date:  2016-04-09       Impact factor: 4.307

8.  Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy.

Authors:  Amber L Mueller; Andrea O'Neill; Takako I Jones; Anna Llach; Luis Alejandro Rojas; Paraskevi Sakellariou; Guido Stadler; Woodring E Wright; David Eyerman; Peter L Jones; Robert J Bloch
Journal:  Exp Neurol       Date:  2019-07-12       Impact factor: 5.330

9.  Upregulated IL-1β in dysferlin-deficient muscle attenuates regeneration by blunting the response to pro-inflammatory macrophages.

Authors:  Tatiana V Cohen; Gina M Many; Bryan D Fleming; Viola F Gnocchi; Svetlana Ghimbovschi; David M Mosser; Eric P Hoffman; Terence A Partridge
Journal:  Skelet Muscle       Date:  2015-08-07       Impact factor: 4.912

10.  Diltiazem improves contractile properties of skeletal muscle in dysferlin-deficient BLAJ mice, but does not reduce contraction-induced muscle damage.

Authors:  Morium Begam; Alyssa F Collier; Amber L Mueller; Renuka Roche; Sujay S Galen; Joseph A Roche
Journal:  Physiol Rep       Date:  2018-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.